In Part 1, Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) speaks to us about the mechanism of action of icosabutate, a novel engineered fatty acid currently under investigation in NASH.
He continues this conversation in Part 2 where we discuss the results from the interim analysis of the ICONA trial (NCT04052516).
His abstract entitled ‘Icosabutate, a novel structurally engineered fatty acid, significantly reduces relevant markers of NASH and fibrosis in 16 weeks: interim analysis results of the ICONA trial’ was presented at the International Liver Congress (ILC) 2021, 23-26 June.
Disclosures: Prof Arun Sanyal has acted as an advisor/board member for Gilead; a consultant for 89 BIO, Affimune, Albireo, Allergan, AMRA, Ardelyx, BASF, Birdrock, Boehringer Ingelheim, Bristol Myers Squibb, Chemomab, Conatus, Durect, Echosans, Enyo, Fractyl, Galectin, General Electric, Genfit, Gilead Hemoshear, Immuron, Indalo, Intercept, Janssen, Lilly, Malinckrodt, Merck, Nimbus, Novartis, Northsea, Novo Nordisk, Perspectum, Pfizer, Poxel, Salix, Sanofi, Second Genome, Servier, Takeda, Terns, Teva, Zydus; received grant/research support from Bristol-Myers Squibb, Conatus, Echosans, Galectin, Gilead, Lilly, Malinckrodt, Merck, Novartis, Novo Nordisk, Fractyl, Madrigal, Inventiva, Covance and Sequana; has stockholder/ownership interest (excluding diversified mutual funds) in Akarna, Durect, Exhalenz, Genfit, Hemoshear, Indalo, Tiziana; is PI for an ongoing trial sponsored by Genfit; has provided advice (no remuneration) to BASF, Galectin, Immuron and has received Royalties from Elsevier and UpToDate.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.
Filmed in coverage of the EASL ILC 2021, 23-26 June.
Share this Video
Related Videos In Liver Disorders
Peter Ferenci, EASL ILC 2022: Wilson’s disease – diagnosis and treatment
Wilson’s disease is a rare, genetic disorder characterized by the accumulation of excess copper in vital organs such as the liver and brain. Damage caused by the excess copper build-up can lead to symptoms of liver and neurological diseases. In this touchENDOCRINOLOGY interview, we speak with Prof. Peter Ferenci (Medical University of Vienna, Vienna, Austria) […]
Camilla Dalby Hansen, EASL ILC 2022: Non-calorie restricted, low carbohydrate, high fat diet for NAFLD in T2DM
touchENDOCRINOLOGY spoke with Camilla Dably Hansen (Odense Hospital, Denmark) about the findings from the recent 6-month randomised controlled trial investigating the impact of a non-calorie restricted, low carbohydrate, high fat diet on nonalcoholic fatty liver disease (NAFLD) activity score (NAS) and HbA1c in patients with type 2 diabetes (T2DM). The abstract entitled ‘A non-calorie restricted […]
Aleksander Krag, EASL 2022: International Liver Congress Update
We caught up with the European Association for the Study of the Liver (EASL) Vice-Secretary, Prof. Aleksander Krag, to discuss the upcoming International Liver Congress (ILC) and what to expect. At ILC 2022 they will be bringing back face-to-face meetings in a new model, reshaping the scientific programme, offering a fresh experience, merging the very best […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!